𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vitamin E Treatment in Tardive Dyskinesia

✍ Scribed by P. N. DANNON; E. LEPKIFKER; I. IANCU; R. ZIV; N. HORESH; M. KOTLER

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
79 KB
Volume
12
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Sixteen patients with tardive dyskinesia were treated with vitamin E in an open trial of on±o±on design. Abnormal involuntary movement scale (AIMS) ratings were performed in every phase of the study. The patients exhibited a signi®cant reduction in their mean AIMS score during vitamin E treatment. Thus, this ®nding may suggest a possible role for vitamin E in the treatment of tardive dyskinesia.

📜 SIMILAR VOLUMES

Butaperazine pharmacokinetics in tardive
Butaperazine pharmacokinetics in tardive dyskinesia
✍ Dr. Marion E. Wolf; Javaid I. Javaid; Aron D. Mosnaim; John M. Davis 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

failed to show any significant differences in the steady-state serum levels of thioridazine or its metabolites between TD and non-TD schizophrenic subjects.

Botulinum toxin as a treatment for tardi
Botulinum toxin as a treatment for tardive dyskinesia
✍ Peter N. van Harten; Ad Hovestadt 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Two older female patients with a history of psychotic depression were treated with a combination of an antipsychotic and an antidepressant. Both developed persistent tardive dyskinesia with severe tongue protrusion. Botulinum toxin was injected into the genioglossal area and the embarrassing tongue

Tardive dyskinesias in the elderly
Tardive dyskinesias in the elderly
✍ G. Fabbrini; P. Barbanti; C. Aurilia 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB
Tardive dyskinesia model in the common m
Tardive dyskinesia model in the common marmoset
✍ Rebecka Klintenberg; Lars Gunne; Per E. Andrén 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

## Abstract Thirteen adult common marmosets (__Callithrix jacchus__) were given once‐monthly injections of haloperidol decanoate (5–15 mg/kg i.m.) for one year. Thereafter, drug‐free and treatment periods alternated at 3‐month intervals. After 2.5 to 14 months, 12 monkeys showed symptoms of tardive

APOE2 allele increased in tardive dyskin
APOE2 allele increased in tardive dyskinesia
✍ Jonathan Halford; Gandis Mazeika; Susan Slifer; Marcy Speer; Ann M. Saunders; Wa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## Abstract Ninety‐seven inpatients with tardive dyskinesia (average AIMS score = 13), the majority of whom were schizophrenic, were studied. Forty patients were Caucasian, and 57 were African–American. The APOE genotypes of these patients were compared to previously published genotypes of controls

A pilot study of verapamil in the treatm
A pilot study of verapamil in the treatment of tardive dyskinesia
✍ Timothy G. Dinan; Claire Capstick 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB 👁 1 views

Six patients with severe and stable tardive dyskinesia were treated with verapamil, a calcium channel blocker, in doses ranging from 240 to 400 mg/day. Weekly assessments were made using the Simpson tardive dyskinesia rating scale. Neuroleptic medication was held constant during the 3-month baseline